Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Friedrich, C; von Bueren, AO; von Hoff, K; Gerber, NU; Ottensmeier, H; Deinlein, F; Benesch, M; Kwiecien, R; Pietsch, T; Warmuth-Metz, M; Faldum, A; Kuehl, J; Kortmann, RD; Rutkowski, S.
Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy.
Neuro Oncol. 2013; 15(2):224-234
Doi: 10.1093/neuonc/nos292
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Benesch Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background. Especially in young children, primitive neuroectodermal tumors of the central nervous system (CNS-PNET) and pineoblastomas are associated with an unfavorable outcome, and only a few prospective trials have been conducted thus far. Methods. From January 2001 through January 2005, 17 eligible children aged <4 years with CNS-PNET not otherwise specified (n = 8), ependymoblastoma (n = 1), or pineoblastoma (n = 8) confirmed by central review were prospectively treated in the trial HIT 2000. In nonmetastatic disease (n = 11), up to 5 postoperative cycles of HIT-SKK systemic multiagent chemotherapy (8 months duration), followed by craniospinal radiotherapy (CSI), were given. In metastatic disease (M1-M3, n = 6), treatment consisted of a shorter induction chemotherapy (2-3 months) with carboplatin and etoposide, followed by tandem high-dose chemotherapy (HDCT) in case of good response to induction. During induction and HDCT, patients received intraventricular methotrexate. CSI was applied to all patients with poor response to induction or residual disease after HDCT and was optional for patients with residual disease before HDCT. Results. Five-year event-free survival and overall survival rates +/- standard error for all eligible patients were 24% +/- 10% and 40% +/- 12%, respectively (median follow-up of survivors: 8.3 years). Only one patient with nonmetastatic disease remained free of relapse/progressive disease during induction. Three of 6 patients with metastatic disease responded to induction and received tandem-HDCT, followed by preventive CSI, and remain in continuous complete remission. Conclusions. Short intensive induction chemotherapy followed by tandem-HDCT in young children with CNS-PNET/pineoblastomas seems to be superior to the prolonged and less intensive induction regimen.
- Find related publications in this database (using NLM MeSH Indexing)
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Brain Neoplasms - mortality Brain Neoplasms - pathology Brain Neoplasms - therapy
- Carboplatin - administration & dosage
- Chemoradiotherapy -
- Child, Preschool -
- Cranial Irradiation -
- Cyclophosphamide - administration & dosage
- Etoposide - administration & dosage
- Female -
- Follow-Up Studies -
- Humans -
- Infant -
- Infant, Newborn -
- Male -
- Methotrexate - administration & dosage
- Neoplasm Grading -
- Neoplasm, Residual - mortality Neoplasm, Residual - pathology Neoplasm, Residual - therapy
- Neuroectodermal Tumors, Primitive - mortality Neuroectodermal Tumors, Primitive - pathology Neuroectodermal Tumors, Primitive - therapy
- Neuropsychological Tests -
- Pineal Gland - drug effects Pineal Gland - pathology Pineal Gland - radiation effects
- Pinealoma - mortality Pinealoma - pathology Pinealoma - therapy
- Prognosis -
- Prospective Studies -
- Quality of Life -
- Survival Rate -
- Vincristine - administration & dosage
- Find related publications in this database (Keywords)
- brain tumors
- chemotherapy
- pineoblastoma
- primitive neuroectodermal tumor (PNET)
- radiotherapy
- young children